Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Payables (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Payables data on record, last reported at $10.1 million in Q3 2025.

  • For Q3 2025, Payables rose 58.77% year-over-year to $10.1 million; the TTM value through Sep 2025 reached $10.1 million, up 58.77%, while the annual FY2024 figure was $2.1 million, 4.29% down from the prior year.
  • Payables reached $10.1 million in Q3 2025 per VRDN's latest filing, up from $8.5 million in the prior quarter.
  • Across five years, Payables topped out at $14.2 million in Q4 2022 and bottomed at $2.1 million in Q4 2024.
  • Average Payables over 5 years is $5.2 million, with a median of $3.7 million recorded in 2023.
  • Peak YoY movement for Payables: skyrocketed 511.16% in 2022, then tumbled 84.27% in 2023.
  • A 5-year view of Payables shows it stood at $2.3 million in 2021, then surged by 511.16% to $14.2 million in 2022, then crashed by 84.27% to $2.2 million in 2023, then decreased by 4.29% to $2.1 million in 2024, then soared by 369.58% to $10.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $10.1 million in Q3 2025, $8.5 million in Q2 2025, and $3.9 million in Q1 2025.